Specificity protein 1 (Sp1)

Specificity protein 1 (Sp1) is a ubiquitous zinc finger transcription factor that plays a fundamental role in regulating the expression of thousands of genes by binding to GC-rich motifs in their promoters (1.4.1, 1.4.3). As a member of the Sp/Krüppel-like family, Sp1 is involved in essential cellular processes including cell growth, differentiation, apoptosis, and the immune response (1.2.1, 1.2.4). While it is necessary for normal development, Sp1 is frequently overexpressed in various malignancies, where it acts as a "non-oncogene addiction" gene that drives the expression of pro-oncogenic factors such as survivin and VEGF (1.1.1, 1.5.3). This overexpression often correlates with poor patient prognosis and resistance to therapy (1.1.3, 1.5.2). Therapeutic strategies targeting the Sp1 pathway include small molecules that inhibit its DNA-binding activity, such as mithramycin, or agents that promote its proteasomal degradation, like certain non-steroidal anti-inflammatory drugs and metformin (1.3.1, 1.3.2). However, the ubiquitous nature of Sp1 and its dual role in regulating both oncogenes and tumor suppressors present significant challenges for achieving therapeutic selectivity and minimizing off-target toxicity (1.5.1, 1.5.2).

Other names

Transcription factor Sp1TSFP1Sp1 transcription factor

Drugs targeting Sp1 typically act by directly interfering with its binding to GC-rich DNA sequences, promoting the proteasomal degradation of the Sp1 protein, or modulating its activity through post-translational modifications and the induction of transcriptional repressors.